Strasbourg, 67, France

  • Featured

    Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

    Phase

    3

    Span

    Sponsor

    Villejuif, Val-de-Marne

    Recruiting

  • Featured

    A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)

    Phase

    3

    Span

    Sponsor

    Mirati

    Paris

    Recruiting

  • Featured

    A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

    For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**

    Phase

    2

    Span

    Sponsor

    Paris, Paris

    Recruiting

  • Featured

    A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

    For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**

    Phase

    3

    Span

    Sponsor

    Villejuif, Villejuif Cedex

    Recruiting

  • Featured

    Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin’s Lymphoma

    See CT.gov: **[**www.clinicaltrials.gov/ct2/show/NCT02501473**](https://www.clinicaltrials.gov/ct2/show/NCT02501473?term=G142&rank=1)**

    Phase

    1/2

    Span

    Sponsor

    Paris, Paris

    Recruiting

  • Featured

    A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

    Study is fully recruited except for MSI high or dMMR endometrial cancer

    Phase

    1

    Span

    Sponsor

    Villejuif, VILLEJUIF CEDEX

    Recruiting

  • Oral Health and Wilson's Disease: SOMAWI

    The comparaison between the three groups is based on evaluation criteria wich is CAOD index of caries severity (developed by Klein and Palmer in 1940) counting the number of permanent teeth with caries (evolving to include non-cavitary caries) (C), absent due to caries (A) and filled (O) in an individual. The maximum score is 28 (third molars are not taken into account). The index is obtained from clinical examination and panoramic dental imaging.

    Phase

    N/A

    Span

    181 weeks

    Sponsor

    Fondation Ophtalmologique Adolphe de Rothschild

    Ivry-sur-Seine

    Recruiting

    Healthy Volunteers

  • Access HBV Assays - European Union (EU) Clinical Trial Protocol -

    Sensitivity to final status on presumed HBV serological marker positive subjects will be calculated. Specificity will be calculated from hospitalized patients and blood donors specimens. False Initial Reactive Rate will be calculated on fresh hospitalized patient samples for Access HBsAg assay only (Qualitative).

    Phase

    N/A

    Span

    346 weeks

    Sponsor

    Beckman Coulter, Inc.

    Ivry-sur-Seine

    Recruiting

  • Periodontitis and Inflammation

    Today, to understand pathogenic mechanisms involved in periodontitis remains a challenge to identify biomarkers or therapeutic targets to improve prevention and screening, as well as the effectiveness of periodontitis treatments. The aim is to characterize, in vivo, specific molecular markers reflecting the activity of the pathology, which could lead to - improve the knowledge of the pathogenesis of periodontitis; - determine target molecules involved in tissue destruction; - determine molecular profiles of patients at local and systemic risk; - determine therapeutic targets The research focuses on the characterization of the immuno-inflammatory response involved in periodontitis. A characterization of the mediators or cells involved will be performed from biological samples (gingival fluid, unstimulated saliva, gingival explants). The gingival fluid is composed of serum inflammatory exudate and inflammatory mediators produced locally in the periodontal pocket. Unstimulated saliva is a biological fluid composed in part of the gingival fluid that drains into it. It has the advantage of being easier to collect (larger quantity, collection by any health professional). This is a non-interventional, cross-sectional, multicenter, prospective, open-label, non-randomized study to collect tissue, crevicular, salivary, and serum samples as part of the patient's routine care in oral medicine departments to form a biological collection. The samples and the clinical data of the patients (excel file with anonymized data and locked by a password) will be transferred to UR2496 for their analysis. Patients will be recruited in the oral medicine departments of AP-HP hospitals (Charles Foix (Ivry/seine) and Henri Mondor (Créteil)) by periodontists in two groups (cases = periodontitis and controls = healthy periodontium but patients requiring surgical care). The time-line of the research is consistent with the usual patient management in oral medicine departments. Inclusion period is 12 months. There is no specific follow-up due to the research. Gingival tissue sampling during surgery of patients will be performed after their inclusion.

    Phase

    N/A

    Span

    144 weeks

    Sponsor

    Assistance Publique - Hôpitaux de Paris

    Ivry-sur-Seine

    Recruiting

    Healthy Volunteers

  • High-definition Surface Electromyography Markers for the Diagnosis of Sarcopenia

    The aging of the population is a major public health problem with its multifactorial impact on quality of life and maintenance of autonomy. Unfortunately, one consequence of aging is sarcopenia, which affects the intrinsic and functional properties of muscle. It is a risk factor for loss of autonomy, falls, frailty and is associated with increased mortality. Sarcopenia is defined as a progressive loss of muscle mass, strength and physical performance. Classically, sarcopenia is assessed by imaging techniques (MRI, DEXA) or bioelectrical impedancemetry for aspects related to the assessment of muscle mass loss. MRI or DEXA are not widely available and/or access is limited. For functional aspects, grip strength measurements are often used. Currently sarcopenia cannot be diagnosed and evaluated by a single examination, including both the morphological (muscle mass) and functional aspects. Furthermore, several biological markers are associated with muscle mass, strength, and function, but these biomarkers are not specific to skeletal muscle and are weakly associated with clinical goals. Finally, despite the important interest in assessing the qualitative/functional and quantitative aspect of skeletal muscle in neuromuscular impairment, there is currently no tool that routinely assesses these aspects. In this context, developing new approaches for non-invasive assessment of sarcopenia, is a major issue. In this pilot project, the investigators aim to develop a medical device derived from high-definition surface electromyography (HD-sEMG) technology, non-invasive and portable, for the diagnosis of sarcopenia.

    Phase

    N/A

    Span

    161 weeks

    Sponsor

    Assistance Publique - Hôpitaux de Paris

    Ivry-sur-Seine

    Recruiting

    Healthy Volunteers

1-10 of 382